Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.
Cell therapies, both autologous and allogeneic, have come a long way in just a few years. Failures, often in clinical stages, have been traced to problems with manufacturing and failure to understand process requirements earlier in the development process.
Download
BioPharm International’s 2015 Outsourcing Resources eBook.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.